By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



111 Speen Street, Suite 306

Framingham  Massachusetts   01701  U.S.A.
Phone: 508-861-7709 Fax: n/a


Key Statistics

Ownership: Private

Web Site: Alzheon


Company News
Alzheon Announces Presentations At Two Upcoming Investor Conferences 11/12/2015 11:40:52 AM
Alzheon Announces Initiation Of Clinical Studies With ALZ-801 Bridging To Pivotal Phase 3 Study In Alzheimer’s Disease 11/6/2015 11:11:38 AM
Alzheon Announces Efficacy Outcomes From Two Prior Tramiprosate Phase 3 Studies 11/6/2015 11:06:31 AM
Alzheon To Present Late-Breaking Presentation At 8th Clinical Trials On Alzheimer’s Disease Congress 10/27/2015 10:28:21 AM
Alzheon To Present At The 2015 Ladenburg Thalmann Healthcare Conference 9/29/2015 11:01:56 AM
Alzheon Appoints Susan Abushakra, M.D., As Chief Medical Officer 9/9/2015 11:04:01 AM
Alzheon To Present At The 22nd Annual NewsMakers In The Biotech Industry Conference 9/8/2015 11:27:30 AM
Alzheon Establishes New Corporate Headquarters 4/8/2015 11:29:17 AM
Raising $10M in Series A, Alzheon CEO Bets He Can Beat Biogen (BIIB) With World's First Alzheimer's Drug 4/8/2015 6:01:58 AM
Alzheon Announces Phase 1 Results Of ALZ-801, A First-in-Class Inhibitor Of Amyloid Formation And Neurotoxicity For Alzheimer’s Disease 3/20/2015 10:20:19 AM